8-benzylthio-n(6)-n-butyladenosine-cyclic-3-5--monophosphate and Heart-Failure

The hemodynamic effects of 8-benzylthio-N6-n butyl adenosine 3',5' cyclic monophosphate (BTB-cAMP) were studied in anesthetized dogs. BTB-cAMP was given intravenously in doses of 1, 3 and 9 mg/kg, respectively. BTB-cAMP induced dose-dependent increases in heart rate, max LV dp/dt, cardiac output and stroke volume, and decreases in mean blood pressure and total peripheral resistance. BTB-cAMP had less of an effect on heart rate and blood pressure than dibutyryl cAMP (DB-cAMP), but showed a greater effect in augmenting cardiac contractility, with earlier manifestations of maximum action. Although the duration of its action is shorter, BTB-cAMP has possible therapeutic applications in cardiovascular diseases such as cardiogenic shock and congestive heart failure. It may also be a better agent than DB-cAMP for the treatment of patients with congestive heart failure because of a less potent hypotensive effect.

Topics: Animals; Blood Pressure; Bucladesine; Cyclic AMP; Dogs; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Injections, Intravenous; Male; Myocardial Contraction; Shock, Cardiogenic; Stroke Volume; Vascular Resistance